| Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia J Vadakekolathu, MD Minden, T Hood, SE Church, S Reeder, H Altmann, ... Science translational medicine 12 (546), eaaz0463, 2020 | 140 | 2020 |
| TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML J Vadakekolathu, C Lai, S Reeder, SE Church, T Hood, A Lourdusamy, ... Blood advances 4 (20), 5011-5024, 2020 | 106 | 2020 |
| The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer MB Jensen, AV Lænkholm, TO Nielsen, JO Eriksen, P Wehn, T Hood, ... Breast Cancer Research 20, 1-10, 2018 | 53 | 2018 |
| Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System. B Wallden, I Pekker, S Popa, N Dowidar, A Sullivan, T Hood, P Danaher, ... Journal of Clinical Oncology 34 (15_suppl), 3034-3034, 2016 | 20 | 2016 |
| Adaptive immune gene signatures correlate with response to flotetuzumab, a CD123× CD3 bispecific DART® molecule, in patients with relapsed/refractory acute myeloid leukemia S Rutella, SE Church, J Vadakekolathu, E Viboch, AH Sullivan, T Hood, ... Blood 132, 444, 2018 | 13 | 2018 |
| Immune gene expression profiling in children and adults with acute myeloid leukemia identifies distinct phenotypic patterns J Vadakekolathu, T Patel, S Reeder, H Schaarschmidt, M Schmitz, ... Blood 130 (Supplement 1), 3942-3942, 2017 | 10 | 2017 |
| Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System. B Wallden, S Ferree, H Ravi, N Dowidar, T Hood, P Danaher, ... Journal of Clinical Oncology 33 (15_suppl), 8536-8536, 2015 | 10 | 2015 |
| Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology. S Rutella, J Vadakekolathu, H Altmann, T Patel, S Reeder, Y Liang, ... Journal of Clinical Oncology 36 (5_suppl), 50-50, 2018 | 9 | 2018 |
| Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma L Sorenson, Y Fu, T Hood, S Warren, TA McEachron Oncoimmunology, 2019 | 8 | 2019 |
| Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med. 2020; 12 (546) J Vadakekolathu, MD Minden, T Hood, SE Church, S Reeder, H Altmann, ... | 5 | |
| TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia C Lai, J Vadakekolathu, S Reeder, SE Church, T Hood, I Aldoss, ... bioRxiv, 2020.02. 28.961391, 2020 | 4 | 2020 |
| Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers DB Freeman, TD Hopkins, PJ Mikochik, JP Vacca, H Gao, A Naylor-Olsen, ... Journal of Medicinal Chemistry 66 (23), 15629-15647, 2023 | 3 | 2023 |
| CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers MAL Day, DC Saffran, T Hood, N Obholzer, A Pandey, A Singhania, ... TC 71, 0.46, 2022 | 3 | 2022 |
| Enabling pathway analysis of RNA expression in formalin-fixed paraffin embedded tissues with the GeoMx DSP Platform G Demirkan, T Hood, J Reeves, Z Norgaard, M Hoang, S Warren, ... Journal of Biomolecular Techniques: JBT 31 (Suppl), S18, 2020 | 3 | 2020 |
| Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple … DC Saffran, MAL Day, N Rioux, T Chen, C Lee, SNA Amara, DB Freeman, ... Cancer Research 82 (4_Supplement), P5-08-05-P5-08-05, 2022 | 2 | 2022 |
| Immune landscapes predict chemotherapy resistance and anti-leukemic activity of flotetuzumab, an investigational CD123× CD3 bispecific Dart® molecule, in patients with relapsed … J Vadakekolathu, MD Minden, T Hood, SE Church, S Reeder, H Altmann, ... Blood 134, 460, 2019 | 2 | 2019 |
| Immune infiltration correlates with TP53 mutational status in a multi-cohort acute myeloid leukemia study S Rutella, J Vadakekolathu, S Reeder, J Ashforth, M Courtney, A Coutts, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | 2 | 2019 |
| Analytical Validation of the nCounter®-based Lymphoma Subtyping Test (LST) for Cell-of-Origin (COO) Identification in Formalin-Fixed Paraffin-Embedded (FFPE) Diffuse Large B … N Chen, S Dennis, P Danaher, B Wallden, T Hood, X Ren, M Liu, ... Blood 128 (22), 2933, 2016 | 2 | 2016 |
| Analytical performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with diffuse large B-cell lymphoma core needle biopsy samples J Storhoff, B Wallden, RM Braziel, C Thieblemont, T Hood, H Ravi, ... Blood 126 (23), 1481, 2015 | 2 | 2015 |
| SYK inhibitors, entospletinib and lanraplenib, show potent anti-leukemic activity in combination with targeted agents LA Carvajal, M McKeown, T Hood, P Kumar, DC Saffran, J DiMartino Blood 140 (Supplement 1), 5932-5933, 2022 | 1 | 2022 |
